{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:34:57Z","timestamp":1791308097466,"version":"4.3.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Inhibitor development is the major treatment complication in children with severe hemophilia A. It is not clear whether the risk of inhibitors is higher with recombinant factor VIII or with plasma-derived factor VIII. We used multivariate analysis to compare 2 cohorts of previously untreated patients (PUPs) with severe hemophilia A: 62 patients treated with the same brand of high-purity plasma-derived FVIII (pFVIII) containing von Willebrand factor (VWF) and 86 patients treated with full-length recombinant FVIII (rFVIII). In addition to the usual end points (all inhibitors, high inhibitors), we also examined a third end point (high inhibitors and\/or immune tolerance induction). The risk of inhibitor development was higher in patients treated with rFVIII than in patients treated with pFVIII, regardless of other risk factors (F8 genotype; nonwhite origin; history of inhibitors in patients with a family history of hemophilia; age at first FVIII infusion). The adjusted relative risk (RRa) for inhibitor development with rFVIII versus pFVIII was 2.4 (all inhibitors), 2.6 (high inhibitors), and 3.2 (high inhibitors and\/or immune tolerance induction), respectively, depending on the end point (above). The pathophysiology of this large effect must be understood in order to improve the characteristics of recombinant products and to reduce the incidence of inhibitors to FVIII.<\/jats:p>","DOI":"10.1182\/blood-2005-04-1371","type":"journal-article","created":{"date-parts":[[2005,9,15]],"date-time":"2005-09-15T20:44:52Z","timestamp":1126817092000},"page":"46-51","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":242,"title":["Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A"],"prefix":"10.1182","volume":"107","author":[{"given":"Jenny","family":"Goudemand","sequence":"first","affiliation":[{"name":"From the Hemophilia Treatment Center (HTC) of University of Lille2, Lille; HTC Paris Assistance Publique\u2013Ho\u0302pitaux de Paris (AP-HP) Ho\u0302pital Necker; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U 720, Paris; Haematology Department, Ho\u0302pital Edouard Herriot, Lyon; HTC Paris AP-HP Ho\u0302pital Bice\u0302tre; HTC Ho\u0302pital de la Timone, Marseille; HTC Ho\u0302pital Co\u0302te de Nacre, Caen; HTC Ho\u0302pital Purpan, Toulouse; Medical University Paris XIII; and INSERM U 689, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Rothschild","sequence":"additional","affiliation":[{"name":"From the Hemophilia Treatment Center (HTC) of University of Lille2, Lille; HTC Paris Assistance Publique\u2013Ho\u0302pitaux de Paris (AP-HP) Ho\u0302pital Necker; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U 720, Paris; Haematology Department, Ho\u0302pital Edouard Herriot, Lyon; HTC Paris AP-HP Ho\u0302pital Bice\u0302tre; HTC Ho\u0302pital de la Timone, Marseille; HTC Ho\u0302pital Co\u0302te de Nacre, Caen; HTC Ho\u0302pital Purpan, Toulouse; Medical University Paris XIII; and INSERM U 689, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Demiguel","sequence":"additional","affiliation":[{"name":"From the Hemophilia Treatment Center (HTC) of University of Lille2, Lille; HTC Paris Assistance Publique\u2013Ho\u0302pitaux de Paris (AP-HP) Ho\u0302pital Necker; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U 720, Paris; Haematology Department, Ho\u0302pital Edouard Herriot, Lyon; HTC Paris AP-HP Ho\u0302pital Bice\u0302tre; HTC Ho\u0302pital de la Timone, Marseille; HTC Ho\u0302pital Co\u0302te de Nacre, Caen; HTC Ho\u0302pital Purpan, Toulouse; Medical University Paris XIII; and INSERM U 689, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Vinciguerrat","sequence":"additional","affiliation":[{"name":"From the Hemophilia Treatment Center (HTC) of University of Lille2, Lille; HTC Paris Assistance Publique\u2013Ho\u0302pitaux de Paris (AP-HP) Ho\u0302pital Necker; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U 720, Paris; Haematology Department, Ho\u0302pital Edouard Herriot, Lyon; HTC Paris AP-HP Ho\u0302pital Bice\u0302tre; HTC Ho\u0302pital de la Timone, Marseille; HTC Ho\u0302pital Co\u0302te de Nacre, Caen; HTC Ho\u0302pital Purpan, Toulouse; Medical University Paris XIII; and INSERM U 689, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lambert","sequence":"additional","affiliation":[{"name":"From the Hemophilia Treatment Center (HTC) of University of Lille2, Lille; HTC Paris Assistance Publique\u2013Ho\u0302pitaux de Paris (AP-HP) Ho\u0302pital Necker; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U 720, Paris; Haematology Department, Ho\u0302pital Edouard Herriot, Lyon; HTC Paris AP-HP Ho\u0302pital Bice\u0302tre; HTC Ho\u0302pital de la Timone, Marseille; HTC Ho\u0302pital Co\u0302te de Nacre, Caen; HTC Ho\u0302pital Purpan, Toulouse; Medical University Paris XIII; and INSERM U 689, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve\u0301","family":"Chambost","sequence":"additional","affiliation":[{"name":"From the Hemophilia Treatment Center (HTC) of University of Lille2, Lille; HTC Paris Assistance Publique\u2013Ho\u0302pitaux de Paris (AP-HP) Ho\u0302pital Necker; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U 720, Paris; Haematology Department, Ho\u0302pital Edouard Herriot, Lyon; HTC Paris AP-HP Ho\u0302pital Bice\u0302tre; HTC Ho\u0302pital de la Timone, Marseille; HTC Ho\u0302pital Co\u0302te de Nacre, Caen; HTC Ho\u0302pital Purpan, Toulouse; Medical University Paris XIII; and INSERM U 689, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Borel-Derlon","sequence":"additional","affiliation":[{"name":"From the Hemophilia Treatment Center (HTC) of University of Lille2, Lille; HTC Paris Assistance Publique\u2013Ho\u0302pitaux de Paris (AP-HP) Ho\u0302pital Necker; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U 720, Paris; Haematology Department, Ho\u0302pital Edouard Herriot, Lyon; HTC Paris AP-HP Ho\u0302pital Bice\u0302tre; HTC Ho\u0302pital de la Timone, Marseille; HTC Ho\u0302pital Co\u0302te de Nacre, Caen; HTC Ho\u0302pital Purpan, Toulouse; Medical University Paris XIII; and INSERM U 689, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se\u0301gole\u0300ne","family":"Claeyssens","sequence":"additional","affiliation":[{"name":"From the Hemophilia Treatment Center (HTC) of University of Lille2, Lille; HTC Paris Assistance Publique\u2013Ho\u0302pitaux de Paris (AP-HP) Ho\u0302pital Necker; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U 720, Paris; Haematology Department, Ho\u0302pital Edouard Herriot, Lyon; HTC Paris AP-HP Ho\u0302pital Bice\u0302tre; HTC Ho\u0302pital de la Timone, Marseille; HTC Ho\u0302pital Co\u0302te de Nacre, Caen; HTC Ho\u0302pital Purpan, Toulouse; Medical University Paris XIII; and INSERM U 689, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Laurian","sequence":"additional","affiliation":[{"name":"From the Hemophilia Treatment Center (HTC) of University of Lille2, Lille; HTC Paris Assistance Publique\u2013Ho\u0302pitaux de Paris (AP-HP) Ho\u0302pital Necker; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U 720, Paris; Haematology Department, Ho\u0302pital Edouard Herriot, Lyon; HTC Paris AP-HP Ho\u0302pital Bice\u0302tre; HTC Ho\u0302pital de la Timone, Marseille; HTC Ho\u0302pital Co\u0302te de Nacre, Caen; HTC Ho\u0302pital Purpan, Toulouse; Medical University Paris XIII; and INSERM U 689, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Calvez","sequence":"additional","affiliation":[{"name":"From the Hemophilia Treatment Center (HTC) of University of Lille2, Lille; HTC Paris Assistance Publique\u2013Ho\u0302pitaux de Paris (AP-HP) Ho\u0302pital Necker; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U 720, Paris; Haematology Department, Ho\u0302pital Edouard Herriot, Lyon; HTC Paris AP-HP Ho\u0302pital Bice\u0302tre; HTC Ho\u0302pital de la Timone, Marseille; HTC Ho\u0302pital Co\u0302te de Nacre, Caen; HTC Ho\u0302pital Purpan, Toulouse; Medical University Paris XIII; and INSERM U 689, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the members of the FVIII-LFB and Recombinant FVIII study groups","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111704040410500_REF1","doi-asserted-by":"crossref","unstructured":"White GC, DiMichele D, Mertens K, et al. Utilisation of previously treated patients (PTPs), non infected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new Factor VIII and Factor IX concentrates: recommendations of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1999;81: 462.","DOI":"10.1055\/s-0037-1614495"},{"key":"2019111704040410500_REF2","unstructured":"European Agency for the Evaluation of Medicinal Products (EMEA). Note for Guidance on the clinical Investigation of plasma derived factor VIII and FIX products. CMP\/BPWG\/198\/95 rev.1(London, 19 October 2000)"},{"key":"2019111704040410500_REF3","unstructured":"US Food and Drug Administration (FDA). Center for Biologics Evaluation and Research (CBER). Workshop on factor VIII inhibitors, Bethesda, MD; November 21, 2003."},{"key":"2019111704040410500_REF4","doi-asserted-by":"crossref","unstructured":"Schwaab R, Brackmann HH, Meyer C, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost. 1995;74: 1402-1406.","DOI":"10.1055\/s-0038-1649954"},{"key":"2019111704040410500_REF5","doi-asserted-by":"crossref","unstructured":"Aledort LM, DiMichele DM. Inhibitors occur more frequently in Africo-American and Latino haemophiliacs. Haemophilia. 1998;4: 68.","DOI":"10.1046\/j.1365-2516.1998.0146c.x"},{"key":"2019111704040410500_REF6","doi-asserted-by":"crossref","unstructured":"Astermark J, Berntorp E. Malmo\u0308 international brother study (MIBS): an international study of brother pairs with haemophilia. Vox Sang. 1999; 77(suppl 1): 80-82.","DOI":"10.1159\/000056723"},{"key":"2019111704040410500_REF7","doi-asserted-by":"crossref","unstructured":"Hay CRM, Ollier W, Pepper L, et al. HLA classe II profile: a weak determinant of factor inhibitor development in severe haemophilia A. Thromb Haemost. 1997;77: 234-237.","DOI":"10.1055\/s-0038-1655944"},{"key":"2019111704040410500_REF8","doi-asserted-by":"crossref","unstructured":"Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EGD, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost. 1997;77: 238-242.","DOI":"10.1055\/s-0038-1655945"},{"key":"2019111704040410500_REF9","doi-asserted-by":"crossref","unstructured":"Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol. 2001;113: 600-603.","DOI":"10.1046\/j.1365-2141.2001.02828.x"},{"key":"2019111704040410500_REF10","doi-asserted-by":"crossref","unstructured":"Van der Bom JG, Mauser-Bunschoten EP, Fischer K, Van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost. 2003;89: 475-479.","DOI":"10.1055\/s-0037-1613376"},{"key":"2019111704040410500_REF11","doi-asserted-by":"crossref","unstructured":"Sharathkumar A, Lillicrap D, Blanchette VS, et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost2003;1: 1228-1236.","DOI":"10.1046\/j.1538-7836.2003.00230.x"},{"key":"2019111704040410500_REF12","doi-asserted-by":"crossref","unstructured":"Koestenberg M, Raith W, Muntean W. High titer inhibitor after continuous factor VIII administration for surgery in young infant. Haemophilia2000;6: 120.","DOI":"10.1046\/j.1365-2516.2000.00377.x"},{"key":"2019111704040410500_REF13","doi-asserted-by":"crossref","unstructured":"Van den Berg HM, Rosendaal G, Voorberg J, Mauser-Bunschoten EP. Inhibitor development in a multitransfused patient with severe haemophilia A. Thromb Haemost. 1999;82: 151-152.","DOI":"10.1055\/s-0037-1614648"},{"key":"2019111704040410500_REF14","doi-asserted-by":"crossref","unstructured":"Aledort LM. Is the incidence and prevalence of inhibitors greater with recombinant products? Yes. J Thromb Haemost. 2004;2: 861-862.","DOI":"10.1111\/j.1538-7836.2004.00731.x"},{"key":"2019111704040410500_REF15","doi-asserted-by":"crossref","unstructured":"Lusher JM. Is the incidence and prevalence of inhibitors greater with recombinant products? No. J Thromb Haemost. 2004;2: 863-865.","DOI":"10.1111\/j.1538-7836.2004.00729.x"},{"key":"2019111704040410500_REF16","doi-asserted-by":"crossref","unstructured":"Gue\u0301rois C, Laurian Y, Rothschild C, et al. Incidence of factor VIII inhibitor development in severe haemophilia A patients treated only with one brand of highly purified plasma-derived concentrate. Thromb Haemost. 1995;73: 215-218.","DOI":"10.1055\/s-0038-1653753"},{"key":"2019111704040410500_REF17","doi-asserted-by":"crossref","unstructured":"Yee TT, Williams MD, Hill FGH, Lee CA, Pasi KJ. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product. Thromb Haemost. 1997;78: 1027-1029.","DOI":"10.1055\/s-0038-1657681"},{"key":"2019111704040410500_REF18","doi-asserted-by":"crossref","unstructured":"Addiego JR, Gomperts E, Liu SL, et al. Treatment of hemophilia with a highly purified factor VIII concentrate prepared by immunoaffinity chromatography. Thromb Haemost. 1992;67: 19-27.","DOI":"10.1055\/s-0038-1648373"},{"key":"2019111704040410500_REF19","doi-asserted-by":"crossref","unstructured":"Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, and the Kogenate Pup study group. Recombinant factor VIII for the treatment of previously untreated patients with haemophilia A. N Engl J Med, 1993;328: 453-459.","DOI":"10.1056\/NEJM199302183280701"},{"key":"2019111704040410500_REF20","unstructured":"Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy and inhibitor risk in previously untreated patient with haemophilia A. Blood. 1994;83: 2428-2435."},{"key":"2019111704040410500_REF21","doi-asserted-by":"crossref","unstructured":"Lusher JM, Lee CA, Kessler CM, Bedrosian CL, and the ReFacto phase 3 study group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients (Pups) with severe haemophilia. Haemophilia. 2003;9: 38-49.","DOI":"10.1046\/j.1365-2516.2003.00708.x"},{"key":"2019111704040410500_REF22","doi-asserted-by":"crossref","unstructured":"Rothschild C, Laurian Y, Satre EP, et al. French previously untreated patients with severe haemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost. 1998;80: 779-783.","DOI":"10.1055\/s-0037-1615358"},{"key":"2019111704040410500_REF23","unstructured":"Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor FVIII inhibitors. Thromb Diath Haemorrh. 1975;34: 869-872."},{"key":"2019111704040410500_REF24","doi-asserted-by":"crossref","unstructured":"Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet. 1993;5: 236-241.","DOI":"10.1038\/ng1193-236"},{"key":"2019111704040410500_REF25","doi-asserted-by":"crossref","unstructured":"Liu Q, Nozari G, Sommer SS. Single-tube polymerase chain reaction for rapid diagnosis of the inversion hotspot of mutation in hemophilia A. Blood. 1998;92: 1458-1459.","DOI":"10.1182\/blood.V92.4.1458"},{"key":"2019111704040410500_REF26","doi-asserted-by":"crossref","unstructured":"Bagnall RD, Waseem N, Green PM, Giannelli F. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood. 2002;99: 168-174.","DOI":"10.1182\/blood.V99.1.168"},{"key":"2019111704040410500_REF27","doi-asserted-by":"crossref","unstructured":"Goodeve A. The incidence of inhibitor development according to specific mutations\u2014and treatment? Blood Coagul Fibrinolysis. 2003;14(suppl 1): S17-S21.","DOI":"10.1097\/00001721-200306001-00005"},{"key":"2019111704040410500_REF28","doi-asserted-by":"crossref","unstructured":"Oldenburg J, Schro\u0308der J, Brackmann HH, Mu\u0308ller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol. 2004;41(suppl 1): 82-88.","DOI":"10.1053\/j.seminhematol.2003.11.016"},{"key":"2019111704040410500_REF29","doi-asserted-by":"crossref","unstructured":"Burnouf T, Burnouf-Radosevich M, Huart JJ, Goudemand M. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography. Vox Sang. 1991;60: 8-15.","DOI":"10.1159\/000461240"},{"key":"2019111704040410500_REF30","doi-asserted-by":"crossref","unstructured":"Gomperts E, Lundblad R, Adamson R. The manufacturing process of recombinant factor VIII, Recombinate. Transf Med Reviews. 1992;4: 247-251.","DOI":"10.1016\/S0887-7963(92)70175-8"},{"key":"2019111704040410500_REF31","doi-asserted-by":"crossref","unstructured":"Boedeker BGD. The manufacturing process of recombinant factor VIII, Kogenate. Transf Med Reviews. 1992;4: 256-260.","DOI":"10.1016\/S0887-7963(92)70177-1"},{"key":"2019111704040410500_REF32","doi-asserted-by":"crossref","unstructured":"Lusher JM. First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Semin Thromb Hemost. 2002;28: 273-276.","DOI":"10.1055\/s-2002-32662"},{"key":"2019111704040410500_REF33","doi-asserted-by":"crossref","unstructured":"White GC II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, on behalf of the factor VIII and factor IX subcommittee. Definitions in hemophilia: recommendation of the Scientific Subcommittee on factor VIII and factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85: 560.","DOI":"10.1055\/s-0037-1615621"},{"key":"2019111704040410500_REF34","doi-asserted-by":"crossref","unstructured":"Andersen PK. Testing goodness of fit of Cox's regression and life model. Biometrics. 1982;38: 67-77.","DOI":"10.2307\/2530289"},{"key":"2019111704040410500_REF35","doi-asserted-by":"crossref","unstructured":"Cox-Gill J. The role of genetics in inhibitor formation. Thromb Haemost. 1999;82: 500-504.","DOI":"10.1055\/s-0037-1615871"},{"key":"2019111704040410500_REF36","doi-asserted-by":"crossref","unstructured":"Ivaskevicius V, Jurgutis R, Rost S, et al. Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data. Br J Haematol. 2001;112: 1062-1070.","DOI":"10.1046\/j.1365-2141.2001.02671.x"},{"key":"2019111704040410500_REF37","doi-asserted-by":"crossref","unstructured":"Vidal F, Farssac E, Altisent C, Puig L, Gallardo D. Rapid hemophilia A molecular diagnosis by a simple DNA sequencing procedure: identification of 14 novel mutations. Thromb Haemost. 2001; 85: 580-583.","DOI":"10.1055\/s-0037-1615637"},{"key":"2019111704040410500_REF38","doi-asserted-by":"crossref","unstructured":"Citron M, Godmilow L, Ganguly T, Ganguly A. High throughput mutation screening of the factor VIII gene (F8C) in hemophilia A: 37 novel mutations and genotype-phenotype correlation. Hum Mutat. 2002;20: 267-274.","DOI":"10.1002\/humu.10119"},{"key":"2019111704040410500_REF39","doi-asserted-by":"crossref","unstructured":"Wadhwa M, Dilger P, Tubbs J, Mire-Sluis A, Barrowcliffe T, Thorpe R. Identification of transforming growth factor-\u03b2 as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in haemophiliacs. Blood. 1994; 84: 2021-2030.","DOI":"10.1182\/blood.V84.6.2021.2021"},{"key":"2019111704040410500_REF40","doi-asserted-by":"crossref","unstructured":"Hodge G, Han P. Effect of intermediate-purity factor VIII (FVIII) concentrate on lymphocyte proliferation and apoptosis: transforming growth factor-\u03b2 is a significant immunomodulatory component of FVIII. Br J Haematol. 2001;115: 376-381.","DOI":"10.1046\/j.1365-2141.2001.03124.x"},{"key":"2019111704040410500_REF41","doi-asserted-by":"crossref","unstructured":"Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost. 2002;88: 221-229.","DOI":"10.1055\/s-0037-1613191"},{"key":"2019111704040410500_REF42","doi-asserted-by":"crossref","unstructured":"Scandella D, deGraaf Mahoney S, Mattingly M, Roeder D, Timmons L, Fulcher A. Epitope mapping of human FVIII inhibitor antibodies by deletion analysis of FVIII fragments expressed in Escherichia coli. Proc Natl Acad Sci U S A. 1988; 85: 6152-6156.","DOI":"10.1073\/pnas.85.16.6152"},{"key":"2019111704040410500_REF43","doi-asserted-by":"crossref","unstructured":"Saenko EL, Ananyeva NM, Kouiavskaia DV, et al. Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action. Haemophilia. 2002;8: 1-11.","DOI":"10.1046\/j.1365-2516.2002.00579.x"},{"key":"2019111704040410500_REF44","doi-asserted-by":"crossref","unstructured":"Raut S, Weller L, Barrowcliffe TW. Phospholipid binding of factor VIII in different therapeutic concentrates. Br J Haematol. 1999;104: 323-329.","DOI":"10.1046\/j.1365-2141.1999.01723.x"},{"key":"2019111704040410500_REF45","unstructured":"Raut S, Di Giambattista M, Bevan SA, Hubbard AR, Barrowcliffe TW, Laub R. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation. Thromb Haemost. 1998;80: 624-631."},{"key":"2019111704040410500_REF46","doi-asserted-by":"crossref","unstructured":"Lin Y, Yang X, Chevrier MC, et al. Relationships between factor VIII: Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates. Haemophilia. 2004;10: 459-469.","DOI":"10.1111\/j.1365-2516.2004.00957.x"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/1\/46\/1279309\/zh800106000046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/1\/46\/1279309\/zh800106000046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T04:04:29Z","timestamp":1573963469000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/1\/46\/21737\/Influence-of-the-type-of-factor-VIII-concentrate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-04-1371","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}